Article Tools/Herramientas de artículos
+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeña






Cancer News Breast Duct Treatment For Early Breast Cancer Eliminates All Signs Of Disease In Laboratory Experiments Next Step Is To Study In Women Receiving Mastectomy Science Daily

Search Related Content

Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Cancer News Breast Duct Treatment For Early Breast Cancer Eliminates All Signs Of Disease In Laboratory Experiments Next Step Is To Study In Women Receiving Mastectomy Science Daily is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.
Search RobinsPost News & Noticias


Cancer News Breast Duct Treatment For Early Breast Cancer Eliminates All Signs Of Disease In Laboratory Experiments Next Step Is To Study In Women Receiving Mastectomy Science Daily | RobinsPost News & Noticias

Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease


Roche's giredestrant cut recurrence risk by 30% in the phase 3 lidERA study, showing strong benefits in early ER-positive breast cancer with a consistent safety profile. Read More

Adjuvant giredestrant improves invasive DFS in early breast cancer subset


Adjuvant giredestrant significantly improved invasive DFS vs. standard-of-care endocrine therapy in patients with early-stage, ER-positive, HER2-negative breast cancer.The findings were presented at ... Read More

Roche's breast cancer drug cuts risk of death by 30% in phase III


Roche RHHBY announced positive new data from a pre-specified interim analysis of its late-stage breast cancer study on pipeline candidate giredestrant, an investigational, oral, potent next-generation ... Read More

Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer


The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ... Read More

Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer: Phase III trial


Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ... Read More

Breast MRI may be safely omitted from diagnostic workup in certain patients with early-stage, HR-negative breast cancer


Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional recurrence whether or not they underwent preoperative breast magnetic resonance ... Read More

Cryoablation: The Minimally Invasive Freezing Technology That’s a Game-Changer for Treating Low-Risk, Early-Stage Breast Cancer


Lumpectomy has been the standard of care for low-risk, early-stage breast cancer, but now cryoablation — freezing cancer tumors to kill them — is emerging as a new option. Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus